[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pruritus-of-unknown-origin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pruritus-of-unknown-origin":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100655458","phase-3-a-study-to-evaluate-efficacy-safety-and-tolerability-of-remibrutinib-in-adult-participants-with-severe-chronic-pruritus-of-unknown-origin-cpuo-100655458",false,"NCT07811869","A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)","A 52-week Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)","Key Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age, at the time of signing the informed consent.\n* Participants with chronic pruritus for at least 4 months prior to screening.\n* Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).\n* Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and\u002For dermatomal in distribution).\n* Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.\n* Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.\n* Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization\u002Fbaseline visit.\n* The average WI-NRS score over the preceding 7 days prior to the randomization\u002Fbaseline visit will be calculated based on the daily WI-NRS scores (0-10).\n* Participants must have PGIS of pruritus scored as 3 \"severe\" at screening and baseline visits.\n\nKey Exclusion Criteria:\n\n* Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.\n* Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.\n* Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and\u002For known or suspected HIV infection.\n* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.\n* Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg\u002Fd or clopidogrel up to 75 mg\u002Fd. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.\n* History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or aspartate aminotransferase (AST)\u002F alanine aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).",[26],"Chronic Pruritus of Unknown Origin",[28,29,30,31,32],"BTK inhibitor","chronic pruritus","chronic pruritus of unknown origin","CPUO","remibrutinib","RECRUITING","2026-10-12",{"date":36,"type":37},"2026-10-13","ACTUAL",{"date":39,"type":37},"2026-10-07",{"date":41,"type":20},"2030-01-03",{"name":43,"class":44},"Novartis Pharmaceuticals","INDUSTRY",7,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":24,"conditions":54,"keywords":55,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100645921","phase-3-a-study-to-evaluate-efficacy-safety-and-tolerability-of-remibrutinib-in-adult-participants-with-severe-chronic-pruritus-of-unknown-origin-cpuo-100645921","NCT07700056","A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)","A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)",{"count":19,"type":20},[23],[26],[28,29,30,31,32],{"date":36,"type":37},{"date":58,"type":37},"2026-08-24",{"date":60,"type":20},"2030-04-15",{"name":43,"class":44},17,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100657140","phase-2-efficacy-and-safety-of-atto-1310-in-the-treatment-of-participants-with-chronic-pruritus-of-unknown-origin-100657140","NCT07833306","Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ATTO-1310 for the Treatment of Participants With Chronic Pruritus of Unknown Origin","Inclusion Criteria:\n\n* Aged 18 to 90 years with a body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 40 kg\u002Fm\\^2.\n* History of chronic pruritus for at least 6 months that is considered of unknown origin (without a clear association to another condition or medication) as assessed by the Investigator.\n* Chronic pruritus must affect at least 2 of the following body areas: legs, arms, or trunk.\n* History of inadequate control of pruritus with at least 1 antihistamine within 6 months of Screening.\n* Patient Global Impression of Severity (PGI-S) of pruritus of \"severe\" at Screening.\n* Use of a stable dose of topical bland emollient twice daily for at least 2 weeks immediately before Day 1\n* Weekly mean of daily WI-NRS ≥7 at Day 1\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* Known condition, other than dry skin, that is considered by the Investigator to be the primary cause of chronic pruritus, including: Presence of a primary dermatologic condition associated with pruritic skin lesions, regional neuropathic pruritus with the exception of peripheral small fiber neuropathy, severe renal failure, hepatobiliary disease, recent infectious dermatoses, suspected somatoform pruritus, ongoing drug-induced pruritus, malignancy or hemopathy, uncontrolled endocrine disease,\n* Liver function tests (bilirubin, AST, ALT, alkaline phosphatase) \\>2.5 times above the upper limit of normal\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m²\n* History of malignancy within 5 years of Screening\n* History of severe or uncontrolled asthma\n* History of known primary immunodeficiency, is considered immunocompromised, or has been treated for a parasitic infection in the past 6 months.\n* History of attempted suicide within the past 2 years.\n* History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV.\n* Active or untreated latent tuberculosis (TB) infection.\n* Any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks before Day 1.\n* History of drug or alcohol abuse within 1 year of Screening","90 Years",{"count":72,"type":20},300,[74],"PHASE2","The goal of this clinical trial is to assess the efficacy and safety of ATTO-1310 in patients with chronic pruritus\u002Fitch of unknown origin.\n\nThe main questions it aims to answer are:\n\nDoes ATTO-1310 treatment alleviate symptoms of itch in participants with chronic pruritus\u002Fitch? What medical problems do participants have when taking ATTO-1310 for 24 weeks? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.",[26],[78,31,79,80],"pruritus","itch","itchy","NOT_YET_RECRUITING","2026-09-16",{"date":84,"type":37},"2026-09-22",{"date":86,"type":20},"2026-12-21",{"date":88,"type":20},"2028-10-30",{"name":90,"class":44},"Attovia Therapeutics Inc"]